Sometimes, More Technology Means More Problems For A Clinical Trial
Source: Clinical Leader
Specialized technology (e.g., remote monitoring of glucose levels, blood pressure, weight) is often touted as the hallmark of a DCT, but more or newer technology doesn’t always mean a trial will run more efficiently. Phil Ambrey, global clinical head at AstraZeneca, gives a firsthand example, concluding with, “I'll be honest, it wasn't perfect.”
View the full presentation here.
This website uses cookies to ensure you get the best experience on our website. Learn more